Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia

Haematologica

Volumn 96, Issue 1, 2011, Pages 33-40

  Gordeuk, Victor R ^a   Minniti, Caterina P ^b   Nouraie, Mehdi ^a   Campbell, Andrew D ^c   Rana, Sohail R ^d   Luchtman Jones, Lori ^e   Sable, Craig ^e   Dham, Niti ^e   Ensing, Gregory ^c   Prchal, Josef T ^f   Kato, Gregory J ^b   Gladwin, Mark T ^g,h   Castro, Oswaldo L ^a  

^a HOWARD UNIVERSITY   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d HOWARD UNIVERSITY   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g Division of Pulmonary   (United States)

^h UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

E Etdi; Hemolysis; Sickle cell anemia; Six minute walk; Tricuspid regurgitation velocity

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FILLING PRESSURE; HEMOLYSIS; HUMAN; LONGITUDINAL STUDY; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; SICKLE CELL ANEMIA; TRICUSPID VALVE REGURGITATION; WALKING;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; FOLLOW-UP STUDIES; HEMOLYSIS; HUMANS; MALE; MITRAL VALVE INSUFFICIENCY; PROSPECTIVE STUDIES; TRICUSPID VALVE INSUFFICIENCY; YOUNG ADULT;

EID: 78650970723     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.030767     Document Type: Article

References (41)

1. Hayag-Barin JE, Smith RE, Tucker FC Jr. Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: a case report and review of the literature. Am J Hematol. 1998;57(1):82-4.
2. Collins FS, Orringer EP. Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies. Am J Med. 1982;73 (6):814-21.
3. Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, Joussef J, Rombos J, Loukopoulos D. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001; 97(11):3411-6.
4. Heller PG, Grinberg AR, Lencioni M, Molina MM, Roncoroni AJ. Pulmonary hypertension in paroxysmal nocturnal hemoglobinuria. Chest. 1992;102(2):642-3.
5. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO 3rd, Schechter AN, Gladwin MT. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12):1383-9.
6. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, et al. Dysregulated arginine metabolism, hemolysis- associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. 2005;294(1):81-90.
7. Machado RF, Gladwin MT. Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol. 2005; 129(4):449-64.
8. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-95.
9. Minniti CP, Sable C, Campbell A, Rana S, Ensing G, Dham N, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica. 2009;94(3): 340-7.
10. Ataga KI, Moore CG, Jones S, Olajide O, Strayhorn D, Hinderliter A, Orringer EP. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol. 2006;134(1):109-15.
11. De Castro LM, Jonassaint JC, Graham FL, Ashley-Koch A, Telen MJ. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol. 2008;83 (1):19-25.
12. Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, Ware RE. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010;116(5):687-692.
13. Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood. 2003;101(4):1257-61.
14. Sachdev V, Machado RF, Shizukuda Y, Rao YN, Sidenko S, Ernst I, et al. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol. 2007;49(4):472-9.
15. Sedrak A, Rao SP, Miller ST, Hekmat V, Rao M. A prospective appraisal of pulmonary hypertension in children with sickle cell disease. J Pediatr Hematol Oncol. 2009;31 (2):97-100.
16. Kato GJ, Onyekwere OC, Gladwin MT. Pulmonary hypertension in sickle cell disease: relevance to children. Pediatr Hematol Oncol. 2007;24(3):159-70.
17. Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease. Pediatrics. 2008;121(4):777-82.
18. Lee MT, Small T, Khan MA, Rosenzweig EB, Barst RJ, Brittenham GM. Dopplerdefined pulmonary hypertension and the risk of death in children with sickle cell disease followed for a mean of three years. Br J Haematol. 2009;146(4):437-41.
19. Liem RI, Young LT, Thompson AA. Prolonged QTc interval in children and young adults with sickle cell disease at steady state. Pediatr Blood Cancer. 2009;52 (7):842-6.
20. Campbell A, Minniti CP, Nouraie M, Arteta M, Rana S, Onyekwere O, et al. Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients. Br J Haematol. 2009;147(3):352-9.
21. Dahoui HA, Hayek MN, Nietert PJ, Arabi MT, Muwakkit SA, Saab RH, et al. Pulmonary hypertension in children and young adults with sickle cell disease: Evidence for familial clustering. Pediatr Blood Cancer. 2009;54(3):398-402.
22. Zilberman MV, Du W, Das S, Sarnaik SA. Evaluation of left ventricular diastolic function in pediatric sickle cell disease patients. Am J Hematol. 2007;82(6):433-8.
23. Hagar RW, Michlitsch JG, Gardner J, Vichinsky EP, Morris CR. Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. Br J Haematol. 2008;140(1):104-12.
24. Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. Br J Haematol. 2009;144(5):736-41.
25. Lai WW, Geva T, Shirali GS, Frommelt PC, Humes RA, Brook MM, et al. Guidelines and standards for performance of a pediatric echocardiogram: a report from the Task Force of the Pediatric Council of the American Society of Echocardiography. J Am Soc Echocardiogr. 2006;19(12):1413-30.
26. Ensing G, Seward J, Darragh R, Caldwell R. Feasibility of generating hemodynamic pressure curves from noninvasive Doppler echocardiographic signals. J Am Coll Cardiol. 1994;23(2):434-42.
27. Pettersen MD, Du W, Skeens ME, Humes RA. Regression Equations for Calculation of Z Scores of Cardiac Structures in a Large Cohort of Healthy Infants, Children, and Adolescents: An Echocardiographic Study. J Am Soc Echocardiogr. 2008;21(8):922-34.
28. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002;15(2):167-84.
29. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol. 1997;30(6):1527-33.
30. ATS statement: guidelines for the sixminute walk test. Am J Respir Crit Care Med. 2002;166(1):111-117.
31. Enright PL. The six-minute walk test. Respir Care. 2003;48(8):783-5.
32. Nixon PA, Joswiak ML, Fricker FJ. A sixminute walk test for assessing exercise tolerance in severely ill children. J Pediatr. 1996;129(3):362-6.
33. Gulmans VA, van Veldhoven NH, de Meer K, Helders PJ. The six-minute walking test in children with cystic fibrosis: reliability and validity. Pediatr Pulmonol. 1996;22(2): 85-9.
34. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010-9.
35. Pont-Kingdon G, Chou LS, Damjanovich K, Sumner K, Herrmann M, Erali M, Lyon E. Multiplex genotyping by melting analysis of loci-spanning probes: beta-globin as an example. Biotechniques. 2007;42(2):193-7.
36. Van Belle G, Fisher LD, Heageny PJ, Lumley T. Biostatistics: A Methodology for the Health Sciences. Second ed. Hoboken: John Wiley & Sons, 2004.
37. Genser B, Cooper PJ, Yazdanbakhsh M, Barreto ML, Rodrigues LC. A guide to modern statistical analysis of immunological data. BMC Immunol 2007;8:27.
38. Raykov T, Marcoulides GA. Path analysis. A First Course in Structural Equation Modeling. Mahwah, NJ: Lawrence Erlbaum Associates, Publishers. 2006;77-116.
39. Anthi A, Machado RF, Jison ML, Taveira- Dasilva AM, Rubin LJ, Hunter L, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med. 2007;175(12):1272-9.
40. Bachir D, Parent F, Hajji L, Inamo J, Loko G, Lionnet F, Driss F, et al. Prospective multicentric survey on pulmonary hypertension (PH) in adults with sickle cell disease. Abstract 572. American Society of Hematology Annual Meeting. New Orelans Louisianna, 2009.
41. NHLBI. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Bethesda, MD: National Institutes of Health, 2005.